Compare Biogen Inc (BIIB) vs United Microelectronics Corp (UMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs United Microelectronics Corp — how do they compare? Biogen Inc trades at $206.51 (market cap $30.13B), while United Microelectronics Corp trades at $19.45 (market cap $47.81B). The key difference: United Microelectronics Corp is the larger of the two by market cap, and United Microelectronics Corp pays a 2.12% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | UMC | |
|---|---|---|
Market Cap | $30.13B | $47.81B |
Sector | Health | Technology |
52-Week High | $216.63 | $28.02 |
52-Week Low | $128.93 | $6.58 |
Enterprise Value | $37.20B | $44.93B |
Dividend Yield | — | 2.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.
Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.
UMC trades at $19.40, up 3.25% with a neutral technical signal. The company reported strong Q2 2026 earnings, beating estimates with $0.54 EPS, and announced fab expansions in Singapore and Taiwan to meet AI demand. Revenue growth is projected to rise to $250.7 billion in 2026, with net income margin improving to 32.75%. Cash flow turned positive in 2025 at $5.66 billion, supporting strategic investments.
Outlook is positive due to AI-driven demand and operational execution, but risks include competitive pressures and capital expenditure volatility. Analysts show mixed sentiment with 26.7% buy ratings, highlighting cautious optimism amid expansion plans.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →
